Schond Greenway joined KaliVir Immunotherapeutics as Chief Financial Officer in August 2024, bringing more than 25 years of experience in corporate finance, capital markets, and strategic leadership across the life sciences sector. He has significant experience leading capital formation, investor engagement, and financial operations for emerging and publicly traded biotechnology companies at critical stages of growth. Prior to KaliVir, Mr. Greenway served as Chief Financial Officer of Definium (formerly Mind Medicine Inc.) and previously held the CFO role at Avalo Therapeutics, with earlier senior finance leadership roles at Mesoblast Ltd., Halozyme Therapeutics, and DURECT Corporation (acquired by Bausch Health). He began his career in investment banking at Morgan Stanley and later served as a healthcare desk research analyst at Barclays Capital. Across his career, he has advised on and executed investment banking transactions exceeding $30 billion and has played a key role in securing more than $1.5 billion in growth equity, private capital, and strategic R&D funding for life sciences companies. Mr. Greenway holds a B.S. in Computer Information Systems from Florida A&M University and an MBA from the Darden School of Business at the University of Virginia.